NgoSepthemba 27, iwebhusayithi esemthethweni ye-CDE yabonisa ukuthi isicelo senkomba entsha kakhilimu we-Pfize Crisaborole (igama lokuhweba laseShayina: Sultanming, igama lokuhweba lesiNgisi: Eucris a, Staquis) samukelwe, okungenzeka ukuthi senzelwe izingane kanye nabantu abadala abaneminyaka eyizinyanga ezi-3 futhi abantu abadala be-atopic dermatitis.

I-Crisaborole iyi-molecule encane, engeyona i-hormonal, i-nonsteroidal anti-inflammatory topical phosphodiesterase 4 (PDE-4) inhibitor eyakhiwe yi-Anacor. NgoMeyi 2016, uPfizer wathola inkampani ngo-$5.2 billion futhi wathola umuthi. NgoZibandlela wonyaka ofanayo, i-Crisaborole yagunyazwa yi-FDA ukuze imakethwe, yaba umuthi wokuqala kadokotela we-atopic dermatitis owavunywa eminyakeni eyi-10, kanye nomuthi wokuqala wangaphandle ongeyona i-steroidal ukuvimbela i-PDE4 yesikhumba.

I-Crisaborole Inhibitors njengesidakamizwa esisha, empeleni, amafomu omthamo womlomo asetshenziselwe ukulinganisa futhi okunzima kwe-plaque psoriasis kanye ne-psoriatic arthritis, umphumela oyinhloko ukungahambi kahle kwamathumbu, ayikho enye ibala elikhethekile.

I-Crisaborole njengezidakamizwa ze-Topical, ingena kancane esikhumbeni, amathuba alo mphumela ohlangothini wokungakhululeki kwamathumbu nawo ancishiswa abe aphansi kakhulu.

Ngenxa yalokho, i-Crisaborole ngokuzumayo yaba "ithemba ledolobhana lonke" kusukela eminyakeni engu-15, odokotela nabazali bebemagange ukuba nokusetshenziswa okuphephile, okuphumelelayo kanye nesikhathi eside kwezidakamizwa ze-topical kude kakhulu.

Usebenza kangakanani umuthi nge-Crisaborole?

Ngo-2016, izifundo ezimbili zesilingo somtholampilo zeSigaba III zaletha izindaba ezijabulisa kakhulu, i-Crisaborole, amafutha okugcoba ama-phosphodiesterase-4 (PDE4) inhibitors, ezigulini ezine-atopic dermatitis engaphezu kweminyaka engu-2 ubudala (izingane nabantu abadala), bathole imiphumela emihle yomtholampilo.